Laserfiche WebLink
will be collected in accordance with federal standards that <br />provide for a continuous chain of custody and which <br />recognize privacy concerns regarding the individuals being <br />tested. <br />2. Testing will be conducted only by accredited labs that have <br />obtained and retained DHHS certification. <br />3. All specimens that are positive in an initial screen. must then <br />be confirmed by as chromatoraphy/mass spectrometry <br />g <br />(GC/MS). GC/MS confirmation is the state-of-the-art drug <br />testing technology, providing a fingerprint of the detected <br />drug. <br />4. A Medical Review Officer (MRO) will review all drug test <br />positives prior to verification of positive test results. The <br />MRO is a physician with specialty -training and expertise in <br />substance abuse and drug testing. The MRO will review <br />confirmed positive test results to ensure proper procedure, <br />protocol, and reporting. The MRO will interview the <br />individual who has a confirmed positive test result by <br />telephone to investigate whether a legal prescription has <br />caused the specimen to test positive. If the individual has no <br />legal prescription, the MRO will take appropriate steps to <br />report a verified positive to the BCRC-Program <br />Administrator, who will then invalidate the employee's <br />certification card. All persons who have tested positive must <br />have their return to work cleared by the EAR <br />5. All positive ,specimens will be retained frozen in a locked <br />facility at the testing laboratory for one (1) year. The retained <br />specimens will be available should the results of that test be <br />disputed or should arbitration or litigation arise out of the <br />actions taken because of the test results. <br />b. On a periodic basis, BCRC will submit blind pre -tested urine <br />samples with appropriate documentation to the drug testing <br />laboratory as a means of assuring itself of laboratory <br />proficiency. <br />